AbTACs	Antibody-based PROTACs
AURKs	Aurora kinases
AUTOTAC	Autophagy-targeting chimera
BBB	Blood–brain barrier
BTK	Bruton tyrosine kinase
c-MET	Cellular mesenchymal-to-epithelial transition factor
CNS	Central nervous system
CRBN	Cereblon
CLL	Chronic lymphocytic leukemia
CSF-1R	Colony-stimulating factor 1 receptor
CR	Complete response
dTAGs	Degradation tags
DC	Dendritic cell
DOR	Duration of response
EFS	Event-free survival
EGFR	Epidermal growth factor receptor
eTPD	Extracellular targeted protein degradation
FGFRs	Fibroblast growth factor receptors
HyT-PD	Hydrophobic tagging-based protein degradation
ICIs	Immune checkpoint inhibitors
IGF-1R	Insulin-like growth factor 1 receptor
IND	Investigational New Drug
LYTACs	Lysosome-targeting chimeras
LTR	Lysosome-targeting receptor
mAbs	Monoclonal antibodies
NMPA	National Medical Products Administration
NEK7	NIMA-related kinase 7
ORR	Overall response rate
AKT	Protein kinase B
POI	Protein of interest
PKIIs	Protein–kinase interaction inhibitors
PPI	Protein–protein interaction
PPIs	Protein–protein interactions
PROTACs	Proteolysis-targeting chimeras
RET	Proto-oncogene tyrosine protein kinase receptor
ROR1	Receptor tyrosine kinase-like orphan receptor 1
RTKs	Receptor tyrosine kinases
ROS1	ROS proto-oncogene 1
SMKIs	Small-molecule kinase inhibitors
TPD	Targeted protein degradation
TRK	Tropomyosin receptor kinase
TME	Tumor microenvironment
TAMs	Tumor-associated macrophages
FDA	U.S. Food and Drug Administration
UC	Urothelial carcinoma